Neurocrine Biosciences Inc
NASDAQ:NBIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
US |
|
Relief Therapeutics Holding SA
OTC:RLFTF
|
CH |
|
Unilever PLC
LSE:ULVR
|
UK |
|
C
|
Conrad Asia Energy Ltd
ASX:CRD
|
ID |
|
Honeywell International Inc
NASDAQ:HON
|
US |
|
Yankuang Energy Group Co Ltd
OTC:YZCHF
|
CN |
|
M
|
Muehl Product & Service AG
F:MPSC
|
DE |
|
Controladora Vuela Compania de Aviacion SAB de CV
BMV:VOLARA
|
MX |
|
G
|
Glencore PLC
F:8GC
|
CH |
|
Aegon NV
AEX:AGN
|
NL |
|
B
|
Bureau Veritas SA
XMUN:4BV
|
FR |
Wall St Price Targets
NBIX Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for NBIX is 191.81 USD with a low forecast of 145.44 USD and a high forecast of 258.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NBIX's stock price target?
Price Target
191.81
USD
According to Wall Street analysts, the average 1-year price target for NBIX is 191.81 USD with a low forecast of 145.44 USD and a high forecast of 258.3 USD.
What is the Revenue forecast for Neurocrine Biosciences Inc?
Projected CAGR
13%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 13%.
What is the Operating Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
26%
Over the last 13 years, the compound annual growth rate for Operating Income has been 53%. The projected CAGR for the next 8 years is 26%.
What is the Net Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
24%
Over the last 13 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 24%.
